Shire to Study ADHD Drug in Preschool-Age Children
the Psychiatry Advisor take:
The FDA has asked drug maker Shire to conduct pediatric clinical studies to investigate the potential use of lisdexamfetamine dimesylate (Vyvanse) to treat attention deficit hyperactivity disorder (ADHD) in kids aged 4 to 5 years -- an age group notoriously understudied in pharmaceutical clinical trials.
Shire is in the midst of designing the three clinical trials of lisdexamfetamine dimesylate. The three studies include a pharmacokinetic study to help determine appropriate dosing, and evaluate safety and tolerability; an efficacy and safety study; and an open-label study to evaluate long-term safety. The first trial is slated to start in the first half of 2015.
FDA Asks Shire to Conduct Trials of Vyvanse in Preschool-Age Children
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Age of Onset of Bipolar Disorder Linked With Substance Use Disorders
- Mind-Body Therapy and Psychiatry: Ancient Tools for Modern Practice
- Marijuana Use Associated With Poorer Depression Outcomes, Increased Suicidal Ideation
- Short Forms of Parent General Behavior Inventory Reliable at Identifying Youth Mood Symptoms
- Low Testosterone Linked With Social Anxiety in Boys With Klinefelter Syndrome
- The Psychology of Hoarding Disorder: Approaches for Treatment
- Smartphone Applications for Depression and Anxiety: Are They Ready for Widespread Use?
- The Many Misconceptions of Catatonia: Treatment Is Often Successful With the Right Knowledge
- Digital Media Engagement Associated With ADHD Symptoms in Adolescents
- Strong Social Networks May Mitigate the Effects of Childhood Adversity
- Unexpected Effect of Substance Use Disorders on Recovery From Bipolar Depression
- Republican Opposition to Obamacare: What's Done, What's to Come
- Early Childhood Out-of-Home Placement Associated With Adverse Outcomes in Adulthood
- Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC
- Integrating Treatments for Opioid Use Disorder and Infectious Diseases